# Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease

> **NCT04419467** · PHASE2 · COMPLETED · sponsor: **CSL Behring** · enrollment: 114 (actual)

## Conditions studied

- Diabetic Kidney Disease (DKD)

## Interventions

- **BIOLOGICAL:** CSL346
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04419467
- **Lead sponsor:** CSL Behring
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-14
- **Primary completion:** 2022-10-24
- **Final completion:** 2022-10-24
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2023-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04419467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04419467, "Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04419467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*